Abstract
More than 90% of epithelial ovarian cancers are clonal neoplasms that arise from the progeny of a single cell (1-3). Comparison of primary and metastatic sites from the same patient has detected similar patterns of loss of heterozygosity (LOH) on different chromosomes, inactivation of the same X chromosome, and identical mutations in the p53 gene in primary and secondary tumors. Given the clonality of most ovarian cancers, multiple genetic alterations must occur in the progeny of a single cell to permit progression from a normal epithelial phenotype to that of a malignant cell capable of uncontrolled proliferation, invasion, and metastasis. Approximately 10% of ovarian cancers are familial and have been associated with germ-line mutations in BRCA1, BRCA2, mismatch repair genes, or p53 (detailed in Subheading 2.2.). Somatic mutations have been found in sporadic ovarian cancers that activate oncogenes or that result in loss of tumor suppressor gene function. Different ovarian cancers can also exhibit aberrant autocrine and/or paracrine growth regulation with alteration in the expression of growth factors and their receptors. No single abnormality has been detected in all ovarian cancers and most of the alterations are observed in cancers that arise at other sites. Certain changes in oncogenes, tumor suppressor genes, growth factors, and their receptors occur in a significant fraction of epithelial ovarian cancers, whereas others are uncommon. Consequently, progress has been made in defining the spectrum and profile of genetic and epigenetic changes that occur during transformation of the ovarian epithelium. A better understanding of the genotypic and phenotypic alterations that are associated with different epithelial ovarian cancers may impact on more effective management of the disease through chemoprevention, early detection, precise prognostication, treatment directed toward molecular targets, and individualization of therapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Jacobs, I. J., Kohler, M. F., Wiseman, R., et al. (1992) Clonal origin of epithelial ovarian cancer: Analysis by loss of heterozygosity, p53 mutation and X chromosome inactivation. J. Natl. Cancer Ins. 84, 1793ā1798.
Mok, C. H., Tsao, W. W., Knapp, R. C., et al. (1992) Unifocal origin of advanced human epithelial ovarian cancer. Cancer Res. 52, 5119ā5122.
Li, S., Han H., Resnik, E., et al. (1993) Advanced ovarian carcinoma: molecular evidence of unifocal origin. Gyn. Onc. 51, 21ā25.
Bast, R. C. Jr. and Mills, G. B. The molecular pathogenesis of ovarian cancer, in The Molecular Basis of Cancer, 2nd ed., Mendelsohn, J., Howley, P., Israel, M., and Liotta, L., in press.
Kim, T. M., Benedict, W. F., Xu, H. J., et al. (1994) Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian epithelial tumors and is associated with normal retinoblastoma gene expression. Cancer Res. 54, 605ā609.
Dodson, M. K., Cliby, W. A., Xu, H. J., et al. (1994) Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res. 54, 610ā613.
Dong, Y., Walsh, M. D., McGuckin, M. A., et al. (1997) Reduced expression of retinoblastoma gene product (pRB) and high expression of p53 are associated with poor prognosis in ovarian cancer. Int. J. Cancer 74, 407ā415.
Marks, J. R., Davidoff, A. M., Kerns, B. J. M., et al. (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 51, 2979ā2984.
Hutson, R., Ramsdale, J., and Wells, M. (1995) p53 protein expression in putative precursor lesions of epithelial ovarian cancer. Histopathol. 27, 367ā371.
Kohler, M. F., Marks, J. R., Wiseman, R. W., et al. (1993) Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J. Natl. Cancer Inst. 85, 1513ā1519.
Schildkraut, J., Bastos, E., and Berchuck, A. (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J. Nat. Cancer Inst. 89, 932ā938.
Henriksen, R., Strang, P., Wilander, E., Backstrom, T., Tribukait, B., and Oberg, K. (1994) p 53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry, Gynecol. Oncol. 53, 301ā306.
Righetti, S. C., Della Torre, G., Pilotti, S., et al. (1996) A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res. 56, 689ā693.
Mujoo, K., Maneval, D. C., Anderson, S. C., and Gutterman, J. U. (1996) Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 12, 1617ā1623.
Mok, S. C., Chan, W. Y., Wong, K. K., et al. (1996) SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene 12, 1895ā1901.
Mok, S. C., Wong, K. K., Chan, R. K., et al. (1994) Molecular cloning of differentially expressed genes in human epithelial ovarian cancer. Gynecol. Oncol. 52, 247ā252.
Patton, S. E., Martin, M. L., Nelson, L. L., et al. (1998) Activation of the Ras-MAP pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res. 58, 2253ā2259.
Yu, Y., Xu, F., Fang, X., Zhao, S., Li, Y., Cuevas, B., et al. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc. Nat. Acad. Sci. USA 96, 214ā219.
Steck, P. A., Pershouse, M. A., Jasser, S. A. et al. (1997) Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Gen. 15, 356ā362.
Abdollahi, A., Godwin, A. K., Miller, P. D., et al. (1997) Indentification of a gene containing zinc finger motifs based on lost expression in malignantly transformed rat ovarian surface epithelial cells. Cancer Res. 57, 2029ā2034.
Schultz, D. C., Vandeweer, L., Berman, D. B., et al. (1996) Identification of two candidate tumor suppressor genes on chromosome 17p13.3. Cancer Res. 56, 1997ā2002.
Slamon, D. J., Godolphin, W., Jones, L. A., et al. (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244, 707ā712.
erchuck, A., Kamel, A., Whitaker, R., et al. (1990) Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 50, 4087ā4091.
u, F. J., Yu, Y. H., Boyer, C. M., et al. (1996) Stimulation or inhibition of ovarian cancer cell proliferation by heregulin is dependent on the ratio of HER2 to HER3 or HER4 expression. Proc. Amer. Assoc. Cancer Res. 37, 191 (A#1305).
Xu, F. J., Stack, S., Boyer, C., et al. (1997) Heregulin and agonistic anti-p185c-erbB2 antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185c-erbB2: Increased invasiveness may contribute to poor prognosis. Clin. Cancer Res. 3, 1629ā1634.
Yu, D., Wu, B., Jing, T., et al. (1998) Overexpression of both p185 c-erbB2 and p170 MDR render breast cancer cells highly resistant to taxol. Oncogene 16, 2087ā2094.
Yu, D., Matin, A., and Xia, W. (1995) Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11, 1383ā1388.
Ueno, N. T., Hung, M. C., and Zhang, S. (1998) Phase I E1 A gene therapy in patents with advanced breast and ovarian cancers. Proc. Amer. Soc. Clin. Oncol. 17, 432a (A#1663).
Xu, F. J., Lupu, R., Rodriguez, G., et al. (1993) Antibody induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of c-erbB-2 (HER-2/neu). Int. J. Cancer 53, 401ā408.
Boente, M. P., Berchuck, A., Whitaker, R. S., KalĆ©n, A., Xu, F. J., Clarke-Pearson, D. L., et al. (1998) Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185erbB-2 in breast and ovarian cancer cell lines. Gynecol. Oncol. 70, 49ā55.
Bae, D. S., Xu, F-J., Mills, G., and Bast, R. C. Jr. (1995) Heregulin and antibodies against p185c-erbB-2 (p185) activate distinct signaling pathways. Proc. Amer. Assoc. Cancer Res. 36, 55 (A#328).
Le, L., Vadlamudi, R., McWatters, A., Kumar, R., and Bast, R. C. Contrasting effects of heregulin and a tumor-inhibitory monoclonal antibody to HER-2 receptor on mitogen-activated protein kinases and phosphoinositide-3-kinase pathways. Proc. Amer. Assoc. Cancer Res., in press.
Adam, L., Vadlamudi, R., Kandapaka, S. B., Chernoff, J., Mendelsohn, J., and Kumar, R. (1998) Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidyl-inositol-3 kinase. J. Biol. Chem. 273, 28,238ā28,246.
Baselga, J., Tripathy, D., Mendelsohn, J., et al. (1996) Phase II study of weekly intravenous recom-binant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Onc. 14, 737ā744.
Baselga, J., Norton, L., Albanell, J., et al. (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825ā2831.
Slamon, D., Leyland-Jones, B., Shak, S., et al. (1998) Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase II trial. Proc. Amer. Soc. Clin. Oncol. 17, 98 (A#377).
McKenzie, S. J., DeSombre, K. A., Bast, B. S., Hollis, D. R., Whitaker, R. S., Berchuck, A., et al. (1993) Serum levels of HER-2/neu (c-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer 71, 3942ā3946.
Berchuck, A., Rodriguez, G. C., Kamel, A., et al. (1991) Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Amer. J. Ob. Gynecol. 164, 669ā674.
Huang, H. J. S., Nagane, M., Klingbiel, C. K., et al. (1997) The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J. Bio. Chem. 272, 2927ā2935.
Ilekis, J. V., Gariti, J., Niederberger, C., et al. (1997) Expression of a truncated epidermal growth factor receptor-like protein (TEGFR) in ovarian cancer. Gynecol. Oncol. 65, 36ā41.
Lidor, Y. J., Xu, F. J., Martinez-Maza, O., et al. (1993) Constitutive production of macrophage colony stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp. Cell Res. 207, 332ā339.
Xu, F. J., Ramakrishnan, S., Daly, L., Soper, J. T., Berchuck, A., Clarke-Pearson, D., et al. (1991) Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Amer. J. Obstet. Gynecol. 165, 1356ā1362.
Kacinski, B. M., Carter, D., Mittal, K., et al. (1990) Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Amer. J. Path. 137, 135ā147.
Wiener, J., Nakano, K., Kruzelock, R. P., Bucana, C. D., Bast, R. C., Jr., and Gallick, G. E. Reduction of c-src kinase activity abrogates malignant human ovarian cancer tumor growth in a xenograft mouse model. Submitted for publication.
Budde, R. J., Ke, S., and Levin, V. A. (1994) Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem. Biophys. 14, 171ā175.
Shayesteh, L., Lu, Y., Ku, W. L., et al. (1999) P1K3CA is implicated as an oncogene in ovarian cancer. Nature Genetics 21, 99ā102.
Bellacosa, A., de Feo, D., Godwin, A. K., et al. (1995) Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int. J. Cancer 64, 280ā285.
nomoto, T., Inoue, M., Perantoni, A. O., et al. (1990) K-ras activation in neoplasms of the human female reproductive tract. Cancer Res. 50, 6139ā6145.
Mok, S. C., Bell, D. A., Knapp, R. C., et al. (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 53, 1489ā1492.
Baker, V. V., Borst, M. P., Dixon, D., et al. (1990) c-myc amplification in ovarian cancer. Gynecol. Onc. 38, 340ā342.
Stromberg, K., Johnson, G. R., OāConnor, D. M., et al. (1994) Frequent immunohistochemical detection of EGF supergene family members in ovarian carcinogenesis. Int. J. Gynecol. Pathol. 13, 342ā347.
Stromberg, K., Collins, T. J., Gordon, A. W., et al. (1992) Transforming growth factor-alpha acts as an autocrine growth factor in ovarian cancer cell lines. Cancer Res. 52, 341ā347.
Ottensmeier, C., Swanson, L., Strobel, T., et al. (1996) Absence of constitutive EGF receptor activa-tion in ovarian cancer cell lines. Brit. J. Cancer 74, 446ā452.
Chambers, S. K., Ivins, C. M., and Carcangiu, M. L. (1997) Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1. Int. J. Cancer 74, 571ā575.
Xu, Y., Gaudette, D. C., Boynton, J., et al. (1994) Characterization of an ovarian cancer activating factor (OCAF) in ascites from ovarian cancer patients. Clin. Cancer Res. 1, 1223ā1232.
Havrilesky, L. J., Hurteau, J. A., Whitaker, R. S., et al. (1995) Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res. 55, 944ā948.
Henriksen, R., Gobl, A., Wilander, E., et al. (1995) Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGF-beta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab. Invest. 73, 213ā220.
Hurteau, J., Rodriguez, G. C., Whitaker, R. S., et al. (1994) Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer 74, 93ā99.
Berchuck, A., Rodriguez, G., Olt, G. J., et al. (1992) Regulation of growth of normal ovarianepithelial cells and ovarian cancer cell lines by transforming growth factor-Ī². Amer. J. Ob. Gynecol. 166, 676ā684.
Baldwin, R. L., Yamada, D., Bristow, R. E., Chen, L-M., and Karlan, B. Y. (1998) Ovarian epithelial growth regulation, in Ovarian Cancer 5, Sharp, F., Blackett, T., Berek, J., Bast, R., eds. Isis Medical Media, Oxford, U.K. pp. 99ā107.
Lafon, C., Mathieu, C., Guerrin, M., et al. (1996) Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ. 7, 1095ā1104.
Rodriguez, G. C., Berchuck, A., Whitaker, R., et al. (1994) Regulation of invasion in ovarian cancer cell lines by transforming growth factor-beta. 26th Annu. Meeting Soc. Gynecol. Oncol. 40.
Lee, M. M., Donahoe, P. K., Hasegawa, T., et al. (1996) Mullerian inhibiting substance in humans: normal levels from infancy to adulthood. J. Clin. Endo. Metabol. 81, 571ā576.
Fuller, A. F., Jr., Guy, S., Budzik, G. P., and Donahoe, P. K. (1982) Mullerian inhibiting substance inhibits colony growth of a human ovarian carcinoma cell line. J. Clin. Endo. Metabol. 54, 1051ā1055.
Wu, S., Boyer, C. M., Whitaker, R. S., et al. (1993) Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 53, 1939ā1944.
Mutch, D. G., Powell, C. B., Kao, M. S., et al. (1992) Resistance to cytolysis by tumor necrosis factor alpha in malignant gynecological cell lines is associated with the expression of protein(s) that prevent the activation of phospholipase A2 by tumor necrosis factor alpha. Cancer Res. 52, 866ā872.
Wu, S., Xu, F. J., Boyer, C. M., and Bast, R. C., Jr. (1994) Proliferation and induction of NF-kappa B by tumor necrosis factor-a can be mediated through two distinct receptors in human ovarian cancer cells. Proc. Amer. Assoc. Cancer Res. 35, 486 (A#2899).
Takeyama, H., Wakamiya, N., OāHara, C., et al. (1991) Tumor necrosis factor expression by human ovarian carcinoma in vivo. Cancer Res. 51, 4476ā4480.
Boyer, C. M., Wu, S., Xu, F-J., et al. (1995) Stimulation of human ovarian cancer cell growth in vivo with TNFa or IL-1 in immunodeficient scid mice. Proc. Amer. Assoc. Cancer Res. 36, 71(A#422).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 2000 Humana Press Inc.
About this protocol
Cite this protocol
Bast, R.C., Mills, G.B. (2000). Alterations in Oncogenes, Tumor Suppressor Genes, and Growth Factors Associated with Epithelial Ovarian Cancers. In: Bartlett, J.M.S. (eds) Ovarian Cancer. Methods in Molecular Medicineā¢, vol 39. Humana Press. https://doi.org/10.1385/1-59259-071-3:37
Download citation
DOI: https://doi.org/10.1385/1-59259-071-3:37
Publisher Name: Humana Press
Print ISBN: 978-0-89603-583-6
Online ISBN: 978-1-59259-071-1
eBook Packages: Springer Protocols